HIV Mutation Detail Information

> M184I Search Result

Mutation Information

Mutation Site	M184I
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Relevant Drug	elvitegravir (EVG);Cobicistat;emtricitabine (FTC);tenofovir (TDF)
Country	European;US

Literature Information

PubMed PMID	33315694
Disease	HIV infection/AIDS
Published Year	2021
Journal	Journal of acquired immune deficiency syndromes (1999)
Title	Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
Author	Perez-Valero I,Llibre JM,Castagna A,Pulido F,Molina JM,Esser S,Margot N,Shao Y,Temme L,Piontkowsky D,McNicholl IR,Haubrich R
Evidence	BACKGROUND: The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance mutations from historical genotypic reports when switching from a tenofovir disoproxil fumarate (TDF)- or abacavir (ABC)-based regimen was investigated.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation